Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Biopharm Knowledge Publishing | The Rise of Mid-Sized Pharma

The Rise of Mid-Sized Pharma

What makes mid-sized companies successful – and what big Pharma can learn from them

Since the year 2000 mid-sized pharmaceutical companies have out performed their larger rivals – they have grown more rapidly, produced better profits and have performed far better on the world’s stock markets.

There are many reasons why this has happened; big pharma is facing a multitude of serious problems that it did not realise were important just a few years ago. Now there are major issues with public perception, an innovation deficit and increased regulation. The lessons for big Pharma are clear and this report provides a challenging analysis of the factors involved, including:

* The failure of the blockbuster model

* R&D productivity

* Therapy Focus

* Specialist markets

* Informed consumers

* The cost of drugs

* Tougher regulation

* Drug withdrawals

The report, written by former Scrip Magazine journalist Jacky Law is published by Biopharm Knowledge Publishing in association with EvaluatePharma® and includes more than 20 tables of EvaluatePharma® information, clearly defining the market and providing evidence to substantiate the arguments made. Interviews with leading industry experts Jo Pisani of PwC and Mike Ward of Nomura Code also form a key part of the report.

This report is essential reading for anyone in the biotech, pharmaceutical and clinical outsourcing industries from corporate management through development and research to marketing and sales. It gives an authoritative, detailed and clear explanation of the issues surrounding mid-sized Pharma and their implications for the market and for the biotech and pharmaceutical industries.

March 2008 PDF
Table of Contents
Price: $1,240.00 / €829.56

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions